Conditions: Myelodysplastic Syndrome
Keywords: Myelodysplastic Syndrome Decitabine Dacogen MGI Pharma
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 99
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the overall response rate in patients with myelodysplastic syndromes (MDS) given a daily dosing schedule of decitabine.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Decitabine
Intervention descriptions: intervention 1: 20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.

Protocol document: